Received Feb 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
received my first Shingrix shot in July 2024 and I have been sick; have not gotten my second shot, is it too late; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of sickness in a patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient did not receive the 2nd dose of Shingrix. In JUL-2024, the patient received the 1st dose of Shingrix. On an unknown date, not applicable after receiving Shingrix and an unknown time after receiving Shingrix, the patient experienced sickness (Verbatim: received my first Shingrix shot in July 2024 and I have been sick) and incomplete course of vaccination (Verbatim: have not gotten my second shot, is it too late). The outcome of the sickness was not reported and the outcome of the incomplete course of vaccination was unknown. It was unknown if the reporter considered the sickness to be related to Shingrix. It was unknown if the company considered the sickness to be related to Shingrix. Additional Information: GSK Receipt Date: 13-FEB-2025 This case was reported by a patient via interactive digital media. The patient received first Shingrix shot and had been sick on and off and have not got the second shot, was it too late to get it now or did have to start over. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination.